{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-024818","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-11-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.182941+00:00","generated_at":"2026-05-16T17:23:10.887282+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Telomir Pharma reports Telomir-1 reduces PSA in prostate cancer cells in dose-related manner","bullets":["Telomir-1 reduced PSA levels in dose-related manner in androgen-responsive human prostate cancer cells (LNCaP) in vitro.","Also associated with reductions in cellular energy metabolism and viability in the same study.","In prior PC3 xenograft mouse model, Telomir-1 reduced tumor volume as single agent; full reduction with paclitaxel combo without mortality.","Paclitaxel alone achieved full tumor reduction but had high mortality; Telomir-1 combo showed no treatment-related deaths.","Company advancing IND-enabling activities for planned IND submission across oncology and aging-related conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-024818","json":"https://secwatch.observer/filing/0001493152-25-024818.json","markdown":"https://secwatch.observer/filing/0001493152-25-024818.md","text":"https://secwatch.observer/filing/0001493152-25-024818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/0001493152-25-024818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225024818/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:23:10.887282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}